Published 2025-02-01
“…Rong-Hua Wang,1 Yin Chen,1 Ya-Ling Lou,1 Yu-Liang Lu,2 Hui-Min Xu3 1Department of Pharmacy, HuZhou Central Hospital (The Fifth School of Clinical Medicine of
Zhejiang Chinese Medical University), Huzhou, People’s Republic of China; 2Department of Cardiology, HuZhou Central Hospital (The Fifth School of Clinical Medicine of
Zhejiang Chinese Medical University), Huzhou, People’s Republic of China; 3Department of Pharmacy, Second Affiliated Hospital,
Zhejiang University School of Medicine, Hangzhou, People’s Republic of ChinaCorrespondence: Rong-Hua Wang, Department of Pharmacy HuZhou Central Hospital (The Fifth School of Clinical Medicine of
Zhejiang Chinese Medical University), No. 1558 Sanhuan North Road, Wuxing District, Huzhou,
Zhejiang, 313000, People’s Republic of China, Email legend.blue@163.com Hui-Min Xu, Department of Pharmacy Second Affiliated Hospital,
Zhejiang University School of Medicine, No. 88 Jiefang Road, Shangcheng District, Hangzhou,
Zhejiang, 310009, People’s Republic of China, Email xuhuimin78@zju.edu.cnPurpose: This study aimed to elaborate on the incidence, clinical features, and management of immune checkpoint inhibitors (ICIs) related cardiovascular adverse events (CVAEs) in real-world practice.Patients and Methods: We performed a retrospective chart review study on patients receiving at least one dose of ICI therapy at a Chinese tertiary hospital from March 2020 to March 2021. …”
Get full text
Article
